Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sofetabart Mipitecan · 1 trial · 4 indications
PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator
| Arm | Type | Description |
|---|---|---|
| Part A: Sofetabart Mipitecan | EXPERIMENTAL | Administered intravenously (IV). |
| Part A: Chemotherapy or Mirvetuximab Soravtansine (MIRV) | ACTIVE_COMPARATOR | Investigator's Choice of Chemotherapy or MIRV given IV. |
| Part B: Sofetabart Mipitecan plus Bevacizumab | EXPERIMENTAL | Administered IV. |
| Part B: Platinum-based Doublet Chemotherapy plus Bevacizumab | ACTIVE_COMPARATOR | Investigator's choice of platinum doublet chemotherapy IV followed by bevacizumab IV. |
| Part C: Sofetabart Mipitecan plus Bevacizumab | EXPERIMENTAL | Administered IV |
| Part C: Platinum-based Doublet Chemotherapy plus Bevacizumab | ACTIVE_COMPARATOR | Investigator's choice of platinum doublet chemotherapy IV followed by bevacizumab IV. |
| Name | Type | Description |
|---|---|---|
| Sofetabart Mipitecan | DRUG | Administered IV |
| Paclitaxel | DRUG | Administered IV |
| Topotecan | DRUG | Administered IV |
| Gemcitabine | DRUG | Administered IV |
| Pegylated liposomal doxorubicin (PLD) | DRUG | Administered IV |
| MIRV | DRUG | Administered IV |
| Bevacizumab | DRUG | Administered IV |
| Carboplatin | DRUG | Administered IV |
Inclusion Criteria: Part A, B, and C: * Have histologically confirmed high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer. * Have confirmed availability of tumor tissue block or slides * Have radiographic progression on or after most recent line of systemic anti...